Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹51Cr
Pharmaceuticals Bulk Drugs & Formulation
Rev Gr TTM
Revenue Growth TTM
-34.68%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

RAJNISH
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 87.2 | 85.8 | 174.6 | 174.7 | 372.5 | 91.5 | -5.9 | -58.1 | -78.6 | -72.0 | -31.1 | 156.5 |
| 7 | 8 | 18 | 21 | 26 | 16 | 17 | 9 | 6 | 4 | 12 | 25 |
Operating Profit Operating ProfitCr |
| -25.2 | 0.3 | 0.2 | 1.3 | 2.0 | 0.0 | 2.8 | 1.4 | -10.6 | 4.0 | -1.9 | -5.9 |
Other Income Other IncomeCr | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | 40.2 | -19.1 | -37.5 | -73.7 | 124.1 | -69.1 | 180.0 | -30.0 | -264.3 | 29.4 | -78.6 | -1,400.0 |
| -20.3 | 6.5 | 0.5 | 0.5 | 1.0 | 1.0 | 1.6 | 0.8 | -8.0 | 4.8 | 0.5 | -3.9 |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 92.2 | 8.7 | 51.5 | -67.0 | -3.0 | 98.2 | -2.3 | 196.9 | -36.7 | -6.2 |
| 13 | 24 | 24 | 35 | 14 | 17 | 27 | 27 | 75 | 49 | 48 |
Operating Profit Operating ProfitCr |
| 3.6 | 4.7 | 12.0 | 15.6 | 1.0 | -23.7 | -0.7 | -4.3 | 2.6 | 0.0 | -4.5 |
Other Income Other IncomeCr | 0 | 0 | 1 | 0 | 0 | 4 | 1 | 2 | 0 | 1 | 1 |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 1 | 4 | 6 | -1 | 0 | 0 | 1 | 1 | 0 | -1 |
| 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| | 97.5 | 281.1 | 74.0 | -114.4 | 116.4 | 293.2 | 17.4 | 124.6 | -83.3 | -730.1 |
| 2.5 | 2.5 | 8.8 | 10.2 | -4.4 | 0.8 | 1.5 | 1.8 | 1.4 | 0.4 | -2.4 |
| 64.7 | 127.7 | 55.7 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 0 | 0 | 3 | 5 | 5 | 5 | 11 | 77 | 77 | 77 | 102 |
| 0 | 1 | 3 | 18 | 17 | 17 | 12 | 6 | 7 | 7 | 8 |
Current Liabilities Current LiabilitiesCr | 5 | 6 | 10 | 9 | 6 | 4 | 4 | 6 | 17 | 4 | 10 |
Non Current Liabilities Non Current LiabilitiesCr | 0 | 1 | 2 | 1 | 6 | 9 | 9 | 10 | 6 | 3 | 2 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 5 | 8 | 17 | 31 | 32 | 33 | 34 | 38 | 81 | 75 | 84 |
Non Current Assets Non Current AssetsCr | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 61 | 25 | 16 | 37 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | -2 | -3 | -9 | -7 | 0 | 0 | -62 | 2 | -4 |
Investing Cash Flow Investing Cash FlowCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
Financing Cash Flow Financing Cash FlowCr | 1 | 3 | 10 | 5 | 0 | 1 | 62 | -2 | -5 |
|
Free Cash Flow Free Cash FlowCr | -2 | -3 | -9 | -7 | 0 | 0 | -62 | 2 | -4 |
| -261.8 | -132.7 | -212.1 | 1,069.7 | 88.4 | -3.0 | -13,493.4 | 164.9 | -2,454.4 |
CFO To EBITDA CFO To EBITDA% | -142.2 | -97.9 | -137.8 | -4,846.4 | -2.8 | 6.6 | 5,592.1 | 86.0 | -60,658.6 |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 70 | 9 | 5 | 88 | 1,276 | 499 | 71 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 16.4 | 0.0 | 53.6 | 226.6 | 1,660.0 | 649.0 | 0.0 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 1.7 | 0.6 | 0.4 | 3.3 | 49.4 | 6.5 | 1.5 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 3.1 | 0.4 | 0.2 | 4.0 | 15.4 | 6.0 | 0.8 |
| 0.4 | 2.2 | 1.1 | 11.2 | 121.7 | -1.6 | -485.6 | -1,157.9 | 254.1 | 10,068.6 |
Profitability Ratios Profitability Ratios |
| 82.4 | 66.6 | 62.4 | 66.8 | 42.4 | -13.2 | 9.3 | 10.5 | 7.4 | 5.8 |
| 3.6 | 4.7 | 12.0 | 15.6 | 1.0 | -23.7 | -0.7 | -4.3 | 2.6 | 0.0 |
| 2.5 | 2.5 | 8.8 | 10.2 | -4.4 | 0.8 | 1.5 | 1.8 | 1.4 | 0.4 |
| 42.2 | 31.1 | 44.8 | 25.1 | 0.9 | 1.9 | 3.4 | 0.7 | 2.2 | 0.6 |
| 86.6 | 63.1 | 40.4 | 19.0 | -2.8 | 0.5 | 1.8 | 0.6 | 1.2 | 0.2 |
| 6.1 | 7.6 | 13.8 | 13.4 | -1.8 | 0.3 | 1.1 | 0.5 | 1.0 | 0.2 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Rajnish Wellness Limited (RWL), incorporated in 2015 and headquartered in Mumbai, is a BSE-listed company focused on the manufacturing, branding, and distribution of **Ayurvedic, pharmaceutical, nutraceutical, and personal care products**. The company operates primarily in the **sexual wellness, energy revitalization, and healthcare segments**, with a growing footprint in the **pharmaceutical retail and lifestyle wellness space**.
RWL combines an **asset-light business model** with **indigenous R&D** and a **pan-India distribution network**, positioning itself as an innovative and scalable player in India’s evolving wellness and healthcare ecosystem.
---
### **Core Business Segments**
RWL operates through two primary business verticals:
1. **PlayWin – Sexual & Lifestyle Wellness**
- Flagship brand launched in 2015, contributing the **majority of company revenues**.
- Focuses on addressing **low libido, stress-induced sexual dysfunction, and personal wellness** for both men and women.
- Offers a complete range of **Ayurvedic sexual wellness products**, including:
- *PlayWin Capsules* (male/female enhancement)
- *PlayWin Oil & Lotion* (personal lubricants and skin care)
- *PlayWin Condoms*
- *Kasaav Powder* (female sexual supplement)
- *Rajnish Malam*
- Products are **FDA-approved**, safe for diabetics and hypertensive patients, and available **over-the-counter** and through medical stores.
- Strong brand recognition in **Maharashtra and North India**, with ongoing expansion into Tier II/III cities and southern states.
2. **Dava Discount – Pharmacy & Healthcare Retail**
- A **franchise-based pharmacy retail chain** launched in 2021, offering **branded medicines at flat discounts (20–25%)** with home delivery.
- Positioned to capitalize on rising demand for **affordable healthcare and online medicine purchases**.
- As of 2025, the network has grown to **over 100 franchise outlets** across India, with ambitious plans to expand further.
- Offers **allopathic, Ayurvedic, and naturopathic products**, creating a **comprehensive wellness platform**.
---
### **Business Model & Operations**
- **Asset-Light Strategy**:
- No in-house manufacturing; outsources production to **GMP-compliant third-party manufacturers** across India.
- Maintains full ownership of **brands, formulations, and intellectual property**.
- Ensures **quality control, regulatory compliance, and on-time delivery** through dedicated supplier partnerships.
- **R&D & Clinical Innovation**:
- In-house **clinical pharmacology unit** conducts studies on complex formulations.
- Uses **indigenously developed technologies** for product development, reducing dependency on imported processes and lowering R&D costs.
- Focus on **safe, effective, and regulatory-compliant formulations**, especially for sensitive categories like sexual wellness.
- **Distribution & Sales Channels**:
- **Pan-India presence** across **21+ states**.
- Network includes:
- **500+ super stockists**
- **10,000+ distributors**
- **100,000+ pharmacy outlets**
- Strong **e-commerce presence** via:
- Snapdeal, IndiaMART, Clickoncare, Lovenaturalremedies, AyurvedMart, Fineyog
- Products available even in **small towns and rural areas**, reflecting deep market penetration.
---
### **Key Strategic Developments (2022–2025)**
#### **Expansion of Dava Discount Franchise**
- Launched in **2021**, Dava Discount has scaled rapidly, with:
- **Flat 25% discount model** (2023–2024) refined to **20%** in company-owned stores (e.g., Malad East, Goregaon).
- Strategic **company-owned outlets** opened in **Mumbai (Goregaon, Malad), Guwahati, Hubli, Howrah**, and other Tier II cities.
- Plans to open **20 new outlets (2024)**, expected to generate **₹300–400 million in annual revenue** with **5–9% operating margins**.
- Franchisees receive **marketing support, territorial exclusivity, and competitive supply pricing**.
#### **Innovative Retail Formats**
- **Medical cum Supermarket** opened in **Malad East, Mumbai (Oct 2023)**:
- Combines **pharmacy services with grocery and daily essentials**, offering **10–80% discounts on non-pharma items**.
- Includes professional **health consultations, ample parking, and home delivery**.
- Aims to create **integrated healthcare-retail hubs** in urban centers.
#### **Strategic Partnership with SSSG (Aug 2022)**
- Collaboration with **Shree Swami Samarth Gurupeeth (SSSG)**, a large Ayurvedic organization with:
- **1,000+ outlets** across India
- **1 million+ daily customers**
- Upcoming **1,000-bed multispecialty hospital**
- Partnership benefits:
- RWL gains **access to SSSG’s vast distribution network**.
- Dava Discount will **supply medicines** to SSSG’s pharmacy and hospital.
- SSSG’s **Ayurvedic and cosmetic products** added to Dava Discount’s portfolio.
- Enhances **omnichannel reach** and strengthens **brand credibility**.
#### **Growth Ambition**
- Goal to open **1,000 Dava Discount stores by 2025** to increase access to **affordable, quality medicines**.
- Expansion targets include **Maharashtra, Gujarat, Tamil Nadu, Andhra Pradesh, and Delhi**.
---
### **Marketing & Branding Strategy**
- **360-degree approach** for PlayWin:
- Utilizes **print, digital, social media, hoardings, public transport, and reality show sponsorships**.
- Conducts **sexual wellness awareness programs** in schools, NGOs, and communities to **destigmatize the category**.
- Led by promoter **Mr. Rajnishkumar S. Singh**, with a focus on **Tier I, II, and III cities**.
- In-house **multi-lingual customer care** team supports consumer engagement and loyalty.
---
### **Corporate & Financial Highlights**
- **Market Position**: Leading Ayurvedic sexual wellness brand with **first-mover advantage** in a niche, high-growth category.
- **Revenue Drivers**: PlayWin (core), Dava Discount (high-growth retail arm).
- **Recent Offer Rejection (Nov 2024)**:
- Declined acquisition offer from **Python Chemical Company Limited**, citing **undervaluation**.
- Management confident in **independent growth trajectory**, supported by **sector tailwinds** and **strong brand equity**.